Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Most healthcare providers follow established clinical protocols when prescribing this medication, adjusting the pace of dose increases based on how each patient responds
To expand reach, both Eli Lilly and Novo Nordisk have partnered with domestic drugmakers to penetrate tier-2 and tier-3 cities
Both medications belong to the class of glucagon-like peptide 1 (GLP-1) agonists, which are approved for the treatment of type 2 diabetes
*In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
US$ 29.24
US$ 28.60
US$ 28.94
US$ 23.59
US$ 20.09
US$ 29.31
US$ 20.34
US$ 26.97
US$ 23.74
US$ 22.61
US$ 25.74
